Biotech company Polaryx Therapeutics revealed on Monday the receipt of US Food and Drug Administration (FDA) Investigational New Drug Application (IND) approval for PLX-200 for the treatment of LINCL (Late Infantile Neuronal Ceroid Lipofuscinosis or CLN2).
Neuronal Ceroid Lipofuscinoses are a group of rare autosomal recessive neurodegenerative lysosomal storage disorders. Among them, LINCL is caused by mutations leading deficiency or loss of function of tripeptidyl peptidase 1 (TPP1). Patients suffer from vision loss, severe seizures and declining motor function, leading to premature death.
The company said PLX-200 is a repurposed drug that binds to the retinoid X receptor-α (RXRα), which binds to PPARα thereby up-regulating the expression of TPP1 mRNA in brain cells via the PPARα/RXRα heterodimer. PLX-200 activates PPARα, which enhances production of transcription factor EB (TFEB) in brain cells. PLX-200 reduces inflammation and prevents cell death (apoptosis).
According to the company, it has advanced a unique repurposing drug development strategy to provide patients with a safe and effective oral treatment option for LINCL.
Additionally, the company is developing its PLX-200 candidate to target this devastating disease and for securing approval from the FDA to proceed with clinical studies to assess the safety, tolerability and efficacy of PLX-200 for children with CLN2 disease.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial